Business Description
Haleos Labs Ltd
ISIN : INE320X01016
Total Employee Number:
592Compare
Compare
Traded in other countries / regions
540679.India IPO Date
2017-08-17Description
Haleos Labs Ltd is engaged in the Business of manufacturing Active Pharmaceutical Ingredients (APIs) and its intermediates and sells its products in India as well as exports. The group sells its products in India and also exports it to other countries. Some of its API products are used in therapy as an Antiulcer, Antifungal, Anti Obesity, Anesthesia, and others. The company has manufacturing facilities at Kazipally and Jeedimetla and its Research and Development center at Sanatnagar in Hyderabad.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.02 | |||||
Equity-to-Asset | 0.47 | |||||
Debt-to-Equity | 0.52 | |||||
Debt-to-EBITDA | 2.35 | |||||
Interest Coverage | 4.35 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 2.27 | |||||
Beneish M-Score | -1.69 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 2.2 | |||||
3-Year EBITDA Growth Rate | 11.7 | |||||
3-Year EPS without NRI Growth Rate | 23.3 | |||||
3-Year FCF Growth Rate | 15.2 | |||||
3-Year Book Growth Rate | 8.2 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 51.53 | |||||
9-Day RSI | 54.59 | |||||
14-Day RSI | 54.57 | |||||
3-1 Month Momentum % | 10.4 | |||||
6-1 Month Momentum % | 7.5 | |||||
12-1 Month Momentum % | 8.31 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.04 | |||||
Quick Ratio | 0.53 | |||||
Cash Ratio | 0.02 | |||||
Days Inventory | 128.23 | |||||
Days Sales Outstanding | 69.68 | |||||
Days Payable | 98.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.09 | |||||
Dividend Payout Ratio | 0.03 | |||||
Forward Dividend Yield % | 0.09 | |||||
5-Year Yield-on-Cost % | 0.09 | |||||
Shareholder Yield % | -0.09 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 37.96 | |||||
Operating Margin % | 8.4 | |||||
Net Margin % | 5.19 | |||||
EBITDA Margin % | 14.11 | |||||
FCF Margin % | -6.18 | |||||
OCF Margin % | 11.15 | |||||
ROE % | 8.42 | |||||
ROA % | 4.19 | |||||
ROIC % | 5.66 | |||||
3-Year ROIIC % | 11.17 | |||||
ROC (Joel Greenblatt) % | 10 | |||||
ROCE % | 11.88 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 27.94 | |||||
PE Ratio without NRI | 27.94 | |||||
Shiller PE Ratio | 27.06 | |||||
PEG Ratio | 4.51 | |||||
PS Ratio | 1.45 | |||||
PB Ratio | 2.26 | |||||
Price-to-Tangible-Book | 2.27 | |||||
Price-to-Operating-Cash-Flow | 12.99 | |||||
EV-to-EBIT | 19.21 | |||||
EV-to-EBITDA | 12.9 | |||||
EV-to-Revenue | 1.82 | |||||
EV-to-FCF | -29.45 | |||||
Price-to-GF-Value | 1.42 | |||||
Price-to-Projected-FCF | 44.3 | |||||
Price-to-Peter-Lynch-Fair-Value | 4.58 | |||||
Price-to-Graham-Number | 1.68 | |||||
Earnings Yield (Greenblatt) % | 5.21 | |||||
FCF Yield % | -4.27 | |||||
Forward Rate of Return (Yacktman) % | 2.95 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Haleos Labs Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 3,337.944 | ||
| EPS (TTM) (₹) | 57.27 | ||
| Beta | 1.1295 | ||
| 3-Year Sharpe Ratio | 0.84 | ||
| 3-Year Sortino Ratio | 1.88 | ||
| Volatility % | 39.2 | ||
| 14-Day RSI | 54.57 | ||
| 14-Day ATR (₹) | 98.770442 | ||
| 20-Day SMA (₹) | 1536.165 | ||
| 12-1 Month Momentum % | 8.31 | ||
| 52-Week Range (₹) | 1050.05 - 1778.35 | ||
| Shares Outstanding (Mil) | 3.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Haleos Labs Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Haleos Labs Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| INR 1.500000 Cash Dividend | 2025-09-24 | 1,200.00 (-2.20%) | ||
| INR 1.500000 Cash Dividend | 2024-09-23 | 1,517.00 (+2.85%) |
Show
Entries
Haleos Labs Ltd Frequently Asked Questions
What is Haleos Labs Ltd(BOM:540679)'s stock price today?
The current price of BOM:540679 is ₹1600.00. The 52 week high of BOM:540679 is ₹1778.35 and 52 week low is ₹1050.05.
When is next earnings date of Haleos Labs Ltd(BOM:540679)?
The next earnings date of Haleos Labs Ltd(BOM:540679) is .
Does Haleos Labs Ltd(BOM:540679) pay dividends? If so, how much?
The Dividend Yield %  of Haleos Labs Ltd(BOM:540679) is 0.09% (As of Today), Highest Dividend Payout Ratio of Haleos Labs Ltd(BOM:540679) was 0.05. The lowest was 0.02. And the median was 0.04. The  Forward Dividend Yield % of Haleos Labs Ltd(BOM:540679) is 0.09%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Haleos Labs Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers